TARA-002

About Protara Therapeutics

Protara Therapeutics is a clinical-stage biotech company with a mission to develop transformative therapies for cancer and rare diseases. Its strategy centers on advancing two distinct, late-stage clinical programs: TARA-002, an investigational cell therapy for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, a phospholipid substrate replacement for intestinal failure-associated liver disease. The company has achieved key milestones by initiating and enrolling multiple Phase 2 trials, positioning both assets for potential near-term data readouts. Protara's focused approach aims to address high-need, niche markets with limited treatment options.

About Protara Therapeutics

Protara Therapeutics is a clinical-stage biotech company with a mission to develop transformative therapies for cancer and rare diseases. Its strategy centers on advancing two distinct, late-stage clinical programs: TARA-002, an investigational cell therapy for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, a phospholipid substrate replacement for intestinal failure-associated liver disease. The company has achieved key milestones by initiating and enrolling multiple Phase 2 trials, positioning both assets for potential near-term data readouts. Protara's focused approach aims to address high-need, niche markets with limited treatment options.

Therapeutic Areas